U.S. flag

An official website of the United States government

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan-.

Cover of StatPearls

StatPearls [Internet].

Show details

Gyromitra Mushroom Toxicity

; ; ; .

Author Information and Affiliations

Last Update: February 9, 2024.

Continuing Education Activity

The false morel mushroom or Gyromitra esculenta is a species often mistaken for the true morels that belong to the Morchella species. "Esculenta" is Latin for "edible," but this mushroom poses a significant health risk when ingested. Gyromitra esculenta produces gyromitrin, which the body can metabolize into the more potent cytotoxin monomethylhydrazine. Patients may present with a gastrointestinal prodrome followed by signs of acute injury to the liver, kidneys, and central nervous system. 

This activity for healthcare professionals enhances learners' proficiency in evaluating and managing Gyromitra mushroom toxicity. This course enhances learners' competence when collaborating with an interprofessional team caring for patients with this condition.

Objectives:

  • Identify the clinical signs and symptoms indicative of Gyromitra mushroom toxicity and differentiate the condition from similarly presenting diseases.
  • Implement immediate and appropriate medical interventions for patients suspected of Gyromitra mushroom toxicity.
  • Evaluate and monitor patients for clinical progression or regression of symptoms associated with Gyromitra mushroom poisoning, adjusting treatment strategies accordingly.
  • Collaborate with an interprofessional team to optimize patient management and outcomes in cases of Gyromitra mushroom toxicity.
Access free multiple choice questions on this topic.

Introduction

Liver Metabolism

Biotransformation reactions in the liver are classified as either phase I or II reactions. Phase I reactions involve the loss or gain of biological activity by hydrolysis or redox reactions. Rarely, substances may retain their bioactivity after undergoing a phase I reaction.

Meanwhile, phase II reactions bind a functional group to the substance being metabolized by a process known as conjugation. Phase II substrates may either be the parent compound or a phase I derivative of this compound. The liver's functional groups for conjugation include endogenous glucuronic acid, sulfate, acetate, glutathione, and amino acids.

Phase I enzyme systems are found mainly in the endoplasmic reticulum. In contrast, phase II enzymes are chiefly cytosolic. Cytochrome P450 isoforms carry out these biotransformation reactions.

γ-Aminobutyric Acid in the Central Nervous System

Some central nervous system (CNS) neurotransmitters are amino acids. The inhibitory neurotransmitter ϒ-aminobutyric acid (GABA) is an example. GABA receptors are ubiquitous in the brain and presynaptic spinal cord neurons, reflecting their important role as neuronal firing regulators. 

GABA receptors are divided into types A, B, and C. GABAA receptors are ligand-gated chloride ion channels and are the most abundant. These receptors are the common targets of antiepileptic drugs, including barbiturates and benzodiazepines. GABAB receptors are G-protein-coupled receptors that inhibit adenylyl cyclase, activate potassium channels, and decrease calcium conductance. Presynaptic GABAB receptors act as autoreceptors that inhibit GABA release. GABAC receptors are transmitter-gated chloride channels and are the least abundant. GABA is much more potent at GABAC than GABAA receptors.

Overview of Gyromitra Toxicity

Mushrooms are the spore-producing fruiting bodies of the kingdom Fungi, with approximately 135,000 species.[1] Of the approximately 5,000 mushroom species hunted by foragers worldwide, only 2% are poisonous to humans.[2] One of these poisonous mushrooms, Gyromitra esculenta, also known as the false morel, has a unique toxicity profile. The mushroom derives its name, "esculenta," from the Latin word for "edible."

Certain cultures consider this mushroom safe to eat, provided that proper preparation techniques, such as parboiling, are used to reduce its toxicity. Unfortunately, several poisoning incidences have been reported in foragers seeking and ingesting this mushroom species. Gyromitra esculenta morphologically resembles true morels belonging to the Morchella species and can thus be confused with this nonpoisonous mushroom (see ImageGyromitra esculenta).[3]

The Gyromitra syndrome consists of a gastrointestinal prodrome occurring more than 5 hours after eating Gyromitra esculenta. Acute liver injury can occur over the next 2 days. Acute kidney injury may occur to a lesser degree. Confusion characterizes acute CNS toxicity in many instances. However, refractory seizures may occur in the most severe cases.

The substance responsible for Gyromitra poisoning is the toxic metabolite monomethylhydrazine (MMH) derived from gyromitrin produced by this mushroom. MMH binds to and inhibits pyridoxal phosphokinase, which activates pyridoxal 5-phosphate, the key cofactor in GABA synthesis. Subsequent GABA depletion leads to CNS excitation and seizures.[4][5][6] MMH is also hepatotoxic and nephrotoxic.

Etiology

Gyromitra esculenta produces the toxin gyromitrin, the metabolite of which causes the manifestations of Gyromitra syndrome. Gyromitra gigas (Snow morel) and Gyromitra fastigiata also contain gyromitrin, but human poisonings have not been attributed to these 2 mushroom species. The gyromitrin content of other Gyromitra species is unknown.[7]

Gyromitrin is a polar, water-soluble, and volatile mycotoxin. Fresh Gyrometria esculenta mushrooms can contain 50 to 300 mg/kg of gyrometrin. Washing, boiling, and drying can significantly reduce the mushrooms' gyrometrin content and make them safe for human consumption.[8][9] 

Toxicity manifests after gyromitrin hydrolysis to MMH. This metabolite is a rocket propellant ingredient responsible for Gyromitra mushroom toxicity. MMH and other hydrazines are cytotoxic, irreversibly blocking cytochrome P450 enzymes, amine oxidases, and glutathione and producing free methyl radicals.[7] Hydrazine compounds also inhibit pyridoxal 5-phosphate formation, an essential GABA synthesis cofactor derived from pyridoxine (vitamin B6).[10] MMH also prevents folinic acid formation by preventing folic acid biotransformation.[11]  

Epidemiology

Gyromitra poisonings have been recorded in Europe and the US over the centuries, although the species names have changed over time. Further investigation enabled the identification of the Gyromitra esculenta mushroom and its toxin. In 1793, poisonings in France were attributed to the then-named Morchella pleopus. In 1885, an extract was obtained from the same mushroom named "helvellic acid." This toxin is now known as gyromitrin. List and Luft identified gyromitrin's chemical structure and properties in 1968.[12]

Most Gyromitra poisonings occur in Eastern Europe, particularly in Germany, Poland, and Finland's conifer forests. In North America, most exposures have been reported in Michigan. However, a less toxic variety grows west of the Rockies, particularly in Idaho and Western Canada. Exposures occur primarily in the spring, unlike other severe mushroom poisonings like Amanita phalloides, which occur more commonly in the fall.[11]

In Sweden, poisoning is relatively frequent due to the mushroom's wide distribution throughout the country. The Swedish Poisons Information Centre received 706 inquiries about human exposure to Gyromitra esculenta between 1994 and 2002. However, the center never reported life-threatening toxicity, and fatalities have not been reported over the last 50 years.[13]

Data from the North American Mycological Association reveal that only 27 cases of Gyromitra esculenta poisoning have been reported in over 30 years. Liver damage was documented in 9 cases (33%) and kidney failure in 3 (11%). No fatalities were reported. Meanwhile, information from the National Poison Data System (NPDS) shows that mushroom toxin exposures represent about 0.2% of the reported cases and appear stable over time. NPDS data also reveal 133,700 cases (7,428 cases yearly) recorded between 1999 and 2016. Of these cases, 703 (0.55%) were from the Gyrometra species, with no reported fatalities.[14] 

Pathophysiology

Gyromitrin is hydrolyzed to N-methyl-N-formyl hydrazine (MFH) in the stomach, then converted in the stomach or liver by cytochrome P450 oxidation into MMH. This active metabolite inhibits mostly enzymatic processes involving pyridoxine derivatives. Gyromitrin directly binds and inhibits pyridoxal phosphokinase, which catalyzes dietary pyridoxine's phosphorylation to pyridoxal 5-phosphate. Pyridoxine activation is similar to the metabolism of the antituberculosis medication isonicotinic acid hydrazide (isoniazid).

Gastrointestinal irritation results from MFH and MMH exposure, manifesting most commonly as nausea, vomiting, abdominal pain, and diarrhea. Renal injury may arise from direct MMH toxicity and dehydration.

The CNS enzyme glutamic acid decarboxylase cannot convert glutamate into GABA without pyridoxal 5-phosphate as a cofactor. GABA depletion reduces the inhibitory effect of presynaptic GABA neurons on postsynaptic firing, resulting in a relative excitatory state in the brain and predisposing to delayed seizures.[15][16]

Liver failure is due to hepatocyte damage from direct MMH exposure. Free radical production and the formulation of an unstable diazonium compound lead to hepatic cell necrosis. MMH also interferes with cytochrome P450, aminooxidases, and glutathione pathways. 

Toxicokinetics

Gyromitrin has the chemical formula C4H8N2O, and its chemical name is N’-ethylidene-N-methylformohydrazide. Gyromitrin's boiling point is 143°C (289°F). In contrast, MMH boils at a lower temperature of 87.5°C (190°F). Parboiling, with subsequent drying, has been cited by various sources as an effective means to detoxify Gyromitra mushrooms and render them edible. This technique can remove about 99% of the mushroom's gyromitrin content.[17]

Michelot estimated gyromitrin's lethal dose to be 25 to 50 mg/kg in adults and 10 to 30 mg/kg in children based on animal experiments. These values roughly correlate to 0.4 to 1.0 kg of fresh, uncooked mushrooms for adults and 0.2 to 0.6 kg for children, amounts unlikely to be consumed at a given time.

Liver acetylation can detoxify MMH. The acetylation rate is influenced genetically. Fast acetylators may not develop toxicity or experience less severe symptoms due to rapid MMH clearance. Genetically slower acetylators are more likely to present with severe gyromitrin toxicity symptoms due to the MMH's longer elimination time.[18]  

History and Physical

Patients may initially present with nausea, vomiting, and abdominal pain. Diarrhea may or may not be reported.[22] Symptoms usually develop 5 to 12 hours after Gyromitra ingestion or generally adhere to the 6-hour rule for mushroom poisoning. Manifestations may also be observed as early as 2 hours post-ingestion.

The time of mushroom ingestion must be elicited on history, as comparing it with the time of symptom onset can help predict clinical severity. Individuals who report emesis within 6 hours of ingestion will likely develop low systemic toxicity, as emesis reduces intestinal gyromitrin absorption and subsequent circulation. However, systemic toxicity risk rises if vomiting begins 6 hours post-ingestion. Intravenous (IV) access must be established for patients with late-onset symptoms with blood collection for laboratory hepatic or renal assessment. IV fluids may also be started to avoid dehydration.[19] The gastrointestinal symptoms are often self-limiting, with most patients recovering in 2-6 days.

Other information that may be obtained are the kind of mushrooms sought, the season of the year, and the amount consumed. Some knowledgeable foragers may even know Gyromitra esculenta and intentionally seek and consume it. Gyromitra mushrooms emerge during the spring in temperate climate forest areas, often near pines and aspen trees. Meanwhile, the amount eaten can also help approximate the likelihood of toxicity as symptom severity correlates with the ingested toxin's quantity.

If the mushrooms were purchased, the store or seller must be identified to help determine if gyromitrin contamination occurred during collection and distribution. The FDA has prohibited the importation of wild mushrooms since the 1980s. Various US states also regulate and limit the sale of wild mushrooms for human consumption.[20]

Physical examination findings are often nonspecific in the early stages but may include dry mucous membranes, decreased bowel sounds, generalized abdominal tenderness, and confusion. Jaundice is a late finding, typically in more severe cases, occurring 3 days post-ingestion. Signs of extensive CNS involvement, including nervousness, vertigo, ataxia, delirium, seizures, and altered mentation, usually occur after large ingestions. A detailed neurologic examination must be performed for patients with CNS symptoms. The ingested amount must also be elicited. Death, although extremely rare, has been reported as early as 3 days post-ingestion.

Toxicity may often go unrecognized in the initial stages of the illness due to the vague presenting complaints. Thus, a high suspicion index for toxic mushroom ingestion is required for diagnosis. Although a rare occurrence, toxic mushroom ingestion must be considered in patients presenting with gastrointestinal complaints after food consumption.

Evaluation

The diagnosis of Gyromitra syndrome is clinical, relying on associating the patient’s liver, renal, and CNS findings with a history of Gyromitra mushroom ingestion. Specific tests for gyromitrin detection are currently unavailable in the clinical setting.

Common laboratory findings in patients with gyromitrin toxicity include elevated transaminases, lactate dehydrogenase, and total bilirubin within 1 to 2 days of ingestion. Liver transaminases, particularly AST, usually peak around 4 to 5 days post-ingestion. Elevated blood urea nitrogen and creatinine may also occur, reflecting acute kidney injury.

CNS signs may vary from confusion to seizures, but computed tomography and magnetic resonance imaging findings are usually normal. Meanwhile, status epilepticus and persistent lateralizing signs warrant further investigation, and neuroimaging must be performed in such cases once the seizure is controlled.

Treatment / Management

Treatment should be initiated as early as possible, especially if seizure development is likely. Initial treatment is primarily supportive, with close attention to fluid and electrolyte balance. Daily laboratory testing should include liver and kidney function tests.

Gastric decontamination is often not required, as vomiting alone may already clear the intestines of the toxin. Specific treatment for any CNS symptoms is pyridoxine supplementation to overcome the vitamin depletion secondary to MMH's action. Pyridoxine at 25 mg/kg IV can be given to control or prevent seizures. Benzodiazepines are also recommended for ongoing seizures despite pyridoxine replacement. Other first-line anticonvulsants, such as phenytoin, are usually ineffective. Most patients recover uneventfully within 6 days with good supportive care and pyridoxine.

Differential Diagnosis

The differential diagnoses of Gyromitra poisoning include the following:

  • Acetaminophen toxicity
  • Amatoxin toxicity
  • Disulfiram toxicity
  • Disulfiram-like mushroom toxicity
  • Diabetic ketoacidosis
  • Gastroenteritis
  • Gallstones (cholelithiasis) and acute cholecystitis 
  • Giardiasis
  • Hyperemesis gravidarum
  • Stimulant abuse
  • Iron toxicity
  • Isoniazid toxicity
  • Orellanine in mushroom toxicity
  • Organophosphate and carbamate toxicity
  • Pediatric gastroenteritis

A detailed clinical evaluation can help distinguish Gyromitra syndrome from these conditions.

Prognosis

The prognosis of Gyromitra mushroom toxicity is very good, and fatalities have not been documented for decades. Less is known about this mushroom than Amanita phalloides in regards to prognostication. However, encephalopathy, renal failure, lactic acidosis, and gastrointestinal symptom onset longer than 8 hours post-ingestion are associated with poor outcomes.

Complications

The potential complications of severe Gyromitra esculenta intoxication include liver and renal failure. Hemodialysis may be required for severe nephrotoxicity. Repeated and chronic Gyromitra handling may result in typical toxic effects, both systemic and local. Additionally, chronic gyromitrin exposure is possibly oncogenic.[23] Gyromitra consumption has also been linked to the development of amyotrophic lateral sclerosis.[24]

Consultations

Consultation with a regional poison center, certified mycologist, or medical toxicologist is often necessary for mushroom identification. Specialists who may be involved in managing organ-specific toxicity include hepatologists, nephrologists, neurologists, and gastroenterologists.

Deterrence and Patient Education

Patient education is the best way to prevent Gyromitra syndrome. Individuals must be counseled about the following:

  • Avoiding consuming known poisonous mushrooms, unidentified mushroom species, or wild varieties purchased from questionable sources
  • Consulting mushroom experts before eating an unrecognizable kind
  • Cooking the mushrooms thoroughly

Even experienced foragers can make mistakes, and the consequences of consuming toxic mushrooms can be severe. Patients must be advised to avoid consuming mushrooms if doubt exists about their edibility. People must also be counseled to seek medical attention immediately if they develop mushroom poisoning symptoms.

Pearls and Other Issues

The most important points to remember when evaluating and managing Gyromitra syndrome are the following:

  • Gyromitra poisoning arises from excessive consumption of Gyromitra esculenta. This mushroom species produces the potentially toxic substance gyromitrin, often resembling edible Morchella mushrooms. 
  • Gyromitrin is metabolized to the potent poison MMH in the body. Parboiling and drying can eliminate this substance from the mushrooms.
  • The initial symptoms of this condition are mainly gastrointestinal, developing within a few hours of mushroom consumption. Late manifestations include liver, kidney, and CNS signs.
  • MFH and MMH are gastrointestinal irritants. Liver involvement occurs due to direct toxic MMH exposure. Renal symptoms are secondary to MMH cytotoxicity, volume depletion, and electrolyte imbalance. CNS injury is due to MMH-induced pyridoxine and consequent GABA depletion.
  • Severe systemic toxicity is less likely if vomiting occurs within 6 hours post-ingestion. Genetically fast acetylators are also less likely to experience serious morbidity.
  • The diagnosis is clinical. Gyromitra poisoning is a unique condition due to the potential for CNS injury, which other mushroom poisoning cases lack. However, diagnostic tests complete the clinical picture by showing deranged liver and kidney function test results after toxic mushroom ingestion. Neuroimaging studies are often unremarkable. No specific tests are clinically available for gyromitrin detection.
  • Management is primarily supportive. Pyridoxine replacement prevents seizures or minimizes recurrence.
  • The condition rarely results in fatalities, especially if treated early.
  • Avoiding Gyromitra esculenta consumption and cooking mushrooms well can help prevent morbidity.

Though rare, Gyromitra esculenta poisoning must be considered in patients presenting with gastrointestinal symptoms after food ingestion. A high suspicion index can help diagnose the condition early and prevent severe systemic toxicity.

Enhancing Healthcare Team Outcomes

Gyromitra poisoning is best managed by an interprofessional team. The professionals who may involved in managing gyromitra poisoning include the following:

  • Emergency medical services are often the first point of contact in cases of acute poisoning. These providers are crucial in providing initial medical care and transporting the individual to the hospital.
  • Emergency medicine physicians are responsible for assessing the patient upon arrival, obtaining a medical history, and conducting a physical examination. These professionals may initiate treatment and coordinate further care based on symptom severity.
  • Medical toxicologists specialize in the study of toxins and poisonings. These experts assist in identifying the specific toxin involved, determining the severity of poisoning, and guiding appropriate treatment strategies. Involvement with a poison control center and medical toxicologist is imperative early in the course of evaluation. 
  • Gastroenterologists may be involved in managing gastrointestinal symptoms. These specialists may also provide expertise in treating gastrointestinal complications.
  • Neurologists, hepatologists, and nephrologists may be involved in managing organ-specific dysfunction caused by Gyromitra poisoning.
  • Intensive care unit team: critical care physicians, nurses, and other ICU staff are essential for managing organ dysfunction, providing life support, and ensuring close monitoring of the patient's condition in severe cases.
  • Clinical pharmacists review medications, suggest available antidotes, and ensure appropriate drug dosages. These professionals collaborate with the healthcare team to minimize drug interactions and optimize therapeutic outcomes.
  • Clinical laboratory staff: analyze blood and urine specimens to determine the severity of poisoning and help guide treatment decisions.
  • Mycologists may assist in identifying the specific mushroom species responsible for the toxicity, which can aid in the patient's management.
  • Nutritionists and dietitians may be involved in the patient's care to address nutritional needs during recovery, especially if gastrointestinal complications affect the patient's ability to eat and absorb nutrients.

Effective communication and collaboration among these professionals are crucial for providing comprehensive and coordinated care to individuals affected by Gyromitra poisoning.

Review Questions

Gyromitra esculenta

Figure

Gyromitra esculenta. This image shows a specimen of the toxic mushroom Gyromitra esculenta, also known as the false morel. Contributed by Vincent Lee, MD

References

1.
Brandenburg WE, Ward KJ. Mushroom poisoning epidemiology in the United States. Mycologia. 2018 Jul-Aug;110(4):637-641. [PubMed: 30062915]
2.
Arłukowicz-Grabowska M, Wójcicki M, Raszeja-Wyszomirska J, Szydłowska-Jakimiuk M, Piotuch B, Milkiewicz P. Acute liver injury, acute liver failure and acute on chronic liver failure: A clinical spectrum of poisoning due to Gyromitra esculenta. Ann Hepatol. 2019 May-Jun;18(3):514-516. [PubMed: 31014949]
3.
Diaz JH. Mistaken Mushroom Poisonings. Wilderness Environ Med. 2016 Jun;27(2):330-5. [PubMed: 27085814]
4.
Zaraf'iants GN. [Forensic medical diagnostics of intoxication with certain poisonous mushrooms in the case of the lethal outcome in a hospital]. Sud Med Ekspert. 2016 Jan-Feb;59(1):22-28. [PubMed: 27030094]
5.
Saviuc P, Harry P, Pulce C, Garnier R, Cochet A. Can morels (Morchella sp.) induce a toxic neurological syndrome? Clin Toxicol (Phila). 2010 May;48(4):365-72. [PubMed: 20507248]
6.
[Mushroom poisonings that we don't think about: Gyromitra poisoning]. Orv Hetil. 2007 Nov 04;148(44):2106. [PubMed: 17959555]
7.
Leathem AM, Dorran TJ. Poisoning due to raw Gyromitra esculenta (false morels) west of the Rockies. CJEM. 2007 Mar;9(2):127-30. [PubMed: 17391587]
8.
Dirks AC, Mohamed OG, Schultz PJ, Miller AN, Tripathi A, James TY. Not all bad: Gyromitrin has a limited distribution in the false morels as determined by a new ultra high-performance liquid chromatography method. Mycologia. 2023 Jan-Feb;115(1):1-15. [PubMed: 36541902]
9.
Pyysalo H, Niskanen A. On the occurrence of N-methyl-N-formylhydrazones in fresh and processed false morel, Gyromitra esculenta. J Agric Food Chem. 1977 May-Jun;25(3):644-7. [PubMed: 558239]
10.
Lagrange E, Vernoux JP. Warning on False or True Morels and Button Mushrooms with Potential Toxicity Linked to Hydrazinic Toxins: An Update. Toxins (Basel). 2020 Jul 29;12(8) [PMC free article: PMC7472412] [PubMed: 32751277]
11.
Michelot D, Toth B. Poisoning by Gyromitra esculenta--a review. J Appl Toxicol. 1991 Aug;11(4):235-43. [PubMed: 1939997]
12.
List PH, Luft P. [Gyromitrin, the poison of Gyromitra esculenta. 16. On the fungi contents]. Arch Pharm Ber Dtsch Pharm Ges. 1968 Apr;301(4):294-305. [PubMed: 5244383]
13.
Karlson-Stiber C, Persson H. Cytotoxic fungi--an overview. Toxicon. 2003 Sep 15;42(4):339-49. [PubMed: 14505933]
14.
Watson WA, Litovitz TL, Rodgers GC, Klein-Schwartz W, Reid N, Youniss J, Flanagan A, Wruk KM. 2004 Annual report of the American Association of Poison Control Centers Toxic Exposure Surveillance System. Am J Emerg Med. 2005 Sep;23(5):589-666. [PubMed: 16140178]
15.
Toth B, Gannett P. Gyromitra esculenta mushroom: a comparative assessment of its carcinogenic potency. In Vivo. 1994 Nov-Dec;8(6):999-1002. [PubMed: 7772753]
16.
Toth B, Gannett P. Carcinogenesis study in mice by 3-methylbutanal methylformylhydrazone of Gyromitra esculenta. In Vivo. 1990 Sep-Oct;4(5):283-8. [PubMed: 2133101]
17.
Lampe KF. Toxic fungi. Annu Rev Pharmacol Toxicol. 1979;19:85-104. [PubMed: 378111]
18.
Lagrange E, Vernoux JP, Reis J, Palmer V, Camu W, Spencer PS. An amyotrophic lateral sclerosis hot spot in the French Alps associated with genotoxic fungi. J Neurol Sci. 2021 Aug 15;427:117558. [PubMed: 34216974]

Disclosure: Keahi Horowitz declares no relevant financial relationships with ineligible companies.

Disclosure: Erwin Kong declares no relevant financial relationships with ineligible companies.

Disclosure: Angela Regina declares no relevant financial relationships with ineligible companies.

Disclosure: B. Zane Horowitz declares no relevant financial relationships with ineligible companies.

Copyright © 2024, StatPearls Publishing LLC.

This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.

Bookshelf ID: NBK470580PMID: 29262102

Views

  • PubReader
  • Print View
  • Cite this Page

Related information

  • PMC
    PubMed Central citations
  • PubMed
    Links to PubMed

Similar articles in PubMed

See reviews...See all...

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...